Cyclosporin A (CsA) remains an important immunosuppressive agent over 20 years after its use.
1 It is important to monitor CsA blood levels to avoid drug toxicity or GVHD.
2 CsA has a narrow therapeutic index and frequent monitoring is needed to maintain an effective concentration. Intravenously administered CsA binds strongly to the inner surface of silastic, silicone or polyurethane central venous lines (CVL), resulting in incorrect (elevated) drug levels.
3-5 Alterations in CsA blood concentration in our allogeneic HSCT patients, in spite of unchanged dose, raised the question of CsA binding to the inner surface of CVL even with oral treatment.
The current study was performed in 11 patients who underwent allogeneic HSCT with individually adjusted nonmyeloablative conditioning. All patients received Sandimmun Neoral s (Novartis, Sweden) in appropriate doses orally. No previous intravenous administration was allowed in these patients. The Emit s 2000 Cyclosporine assay (Dade Behring Inc.) was used for quantitative analysis of CsA as described by the manufacturer. The assays were performed on the COBAS MIRA s chemistry system. This monoclonal immunoassay is highly specific for the parent drug, and has a coefficient of variation that is o15%.
We compared drug levels in blood samples obtained from CVLs and peripheral circulation. The CsA blood concentrations in patients also showed a large interindividual variability from 29 to 308 nmol/l. A good correlation was seen between peripheral vein samples and CVL (Figure 1; Po0.0001 ). There were no clinically significant differences between the two concentrations.
These data indicate that oral CsA therapy can be monitored using CVL samples and that no sampling error due to drug adsorbed to the CVL catheters occur in these patients. However, if patients have ever received intravenous CsA through the CVL, blood samples should be obtained peripherally. 
